Key terms

About VRDN

Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product candidates include Cobomarsen, which treats patients with certain cancers, including cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma, and Remlarsen and MRG-229, which are made for the treatment of patients with pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest VRDN news

Apr 16 7:09am ET Foghorn Therapeutics appoints Humer as Chief Financial Officer by TipRanks Apr 12 7:10am ET Analysts Offer Insights on Healthcare Companies: Prime Medicine, Inc. (PRME), Arvinas Holding Company (ARVN) and Viridian Therapeutics (VRDN) by TipRanks Apr 05 8:55am ET Buy Rating Affirmed for Viridian Therapeutics Amidst TED Treatment Market Potential by TipRanks Mar 24 9:40pm ET Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN), OmniAb (OABI) and Vericel (VCEL) by TipRanks Mar 21 8:46am ET Viridian Therapeutics price target lowered to $25 from $29 at B. Riley by TipRanks Mar 21 6:40am ET Analysts Offer Insights on Healthcare Companies: Taysha Gene Therapies (TSHA) and Viridian Therapeutics (VRDN) by TipRanks Mar 20 3:35pm ET Buy Rating Endorsed for Viridian Therapeutics’ VRDN Treatments Based on Superior Efficacy and Dosing Advantages in TED Market by TipRanks Mar 20 2:35pm ET Buy Rating Affirmed for Viridian Therapeutics Amid Strong Competitive Position and Promising Drug Prospects by TipRanks Mar 20 1:15pm ET Viridian Therapeutics Leads in Thyroid Eye Disease Treatments: Superior Efficacy and Promising Pipeline Justify Buy Rating by TipRanks Mar 01 1:00am ET Buy Rating Affirmed for Viridian Therapeutics Amid Strong Clinical Progress and Market Potential by TipRanks Feb 29 8:06am ET Oppenheimer Remains a Buy on Viridian Therapeutics (VRDN) by TipRanks Feb 29 7:24am ET Analysts Offer Insights on Healthcare Companies: UnitedHealth (UNH), Catalyst Pharma (CPRX) and Viridian Therapeutics (VRDN) by TipRanks Feb 29 7:22am ET Viridian Therapeutics (VRDN) Gets a Buy from RBC Capital by TipRanks Feb 29 6:39am ET Viridian Therapeutics: A Strong Buy on TED Treatment Prospects and Financial Stability by TipRanks Feb 29 6:16am ET Viridian Therapeutics price target lowered to $37 from $39 at Wells Fargo by TipRanks Feb 29 5:40am ET Buy Rating on Viridian Therapeutics Backed by Pipeline Progress and Phase 3 Trial Potential by TipRanks Feb 28 8:49am ET Viridian Therapeutics price target raised to $40 from $39 at Wedbush by TipRanks Feb 28 7:23am ET Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN), Masimo (MASI) and Johnson & Johnson (JNJ) by TipRanks Feb 28 7:15am ET Buy Rating for Viridian Therapeutics Backed by Strong Financials and Promising Drug Candidate by TipRanks Feb 28 7:10am ET Analysts Offer Insights on Healthcare Companies: Tarsus Pharmaceuticals (TARS), Protagonist Therapeutics (PTGX) and Viridian Therapeutics (VRDN) by TipRanks Feb 28 7:09am ET Viridian Therapeutics: A Promising Investment on the Brink of Key Milestones in Thyroid Eye Disease Treatment by TipRanks Feb 28 6:50am ET Analysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (PRCT), Pliant Therapeutics (PLRX) and Viridian Therapeutics (VRDN) by TipRanks Feb 28 6:44am ET Viridian Therapeutics price target lowered to $37 from $38 at JMP Securities by TipRanks Feb 28 12:55am ET Buy Rating Affirmed for Viridian Therapeutics Amid Strong Drug Pipeline Progress and Robust Financial Position by TipRanks Feb 27 4:08pm ET Viridian Therapeutics expects cash to fund operations into second half of 2026 by TipRanks Feb 27 4:07pm ET Viridian Therapeutics reports Q4 EPS ($1.35), consensus ($1.00) by TipRanks Feb 16 8:06am ET Viridian Therapeutics names Jennifer Tousignant chief legal officer by TipRanks Jan 25 6:44am ET Insider Trading: Viridian (NASDAQ:VRDN) Sees Huge Insider Buy by TipRanks Jan 22 8:31am ET Viridian Therapeutics price target lowered to $39 from $40 at Wedbush by TipRanks Jan 17 10:45pm ET Viridian Therapeutics 7.14M share Spot Secondary priced at $21.00 by TipRanks Jan 17 4:05pm ET Viridian announces offering of common stock, Series B preferred stock by TipRanks
Mar 14 4:15am ET SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Viridian Therapeutics, Inc. (VRDN) and Encourages Investors to Contact the Firm by Newsfile

VRDN Financials

1-year income & revenue

Key terms

VRDN Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

VRDN Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms

Latest investing news

A bubble tea store operated by Sichuan Baicha Baidao in Shanghai, China, on April 23, 2024.
Raul Ariano/Bloomberg/Getty Images
Is the tea bubble bursting? ChaPanda shares plunge in Hong Kong IPO
People walk past the New York Stock Exchange (NYSE) on April 10, 2024 in New York City.
Spencer Platt/Getty Images
Can markets make a comeback? That depends on tech earnings
People walk past the New York Stock Exchange Thursday, March. 21, 2024.
Yuki Iwamura/AP
Investors are fearful. They shouldn’t be
People walk past the New York Stock Exchange (NYSE) on March 28, 2024 in New York City.
NDZ/STAR MAX/IPx/AP
What stalled this year’s seemingly infallible stock market rally